Page 65 - 《中国药房》2025年11期
P. 65

Hepatol,2019,16(6):377-386.                    [16]  ZHAO H,GAO X,LIU Z Z,et al. Sodium alginate pre‐
          [ 2 ]  YOUNOSSI Z M,KOENIG A B,ABDELATIF D,et al.       vents non-alcoholic fatty liver disease by modulating the
              Global  epidemiology  of  nonalcoholic  fatty  liver  disease:  gut-liver axis in high-fat diet-fed rats[J]. Nutrients,2022,
              meta-analytic  assessment  of  prevalence,incidence,and   14(22):4846.
              outcomes[J]. Hepatology,2016,64(1):73-84.      [17]  RODRIGUEZ-DIAZ C,TAMINIAU B,GARCÍA-GARCÍA
          [ 3 ]  FRIEDMAN  S  L,NEUSCHWANDER-TETRI  B  A,         A,et  al.  Microbiota  diversity  in  nonalcoholic  fatty  liver
              RINELLA M,et al. Mechanisms of NAFLD development    disease  and  in  drug-induced  liver  injury[J].  Pharmacol
              and  therapeutic  strategies[J].  Nat  Med,2018,24(7):  Res,2022,182:106348.
              908-922.                                       [18]  YIN H G,HUANG J H,GUO X Z,et al. Romboutsia li‐
          [ 4 ]  TARGHER  G,BYRNE  C  D,TILG  H.  NAFLD  and  in‐  tuseburensis JCM1404 supplementation ameliorated endo‐
              creased  risk  of  cardiovascular  disease:clinical  associa‐  thelial  function  via  gut  microbiota  modulation  and  lipid
              tions,pathophysiological  mechanisms  and  pharmacologi‐  metabolisms alterations in obese rats[J]. FEMS Microbiol
              cal implications[J]. Gut,2020,69(9):1691-1705.      Lett,2023,370:fnad016.
          [ 5 ]  国家药典委员会 . 中华人民共和国药典:一部[M].2020              [19]  TENG S S,ZHANG Y F,JIN X H,et al. Structure and
              年版.北京:中国医药科技出版社,2020:321.                           hepatoprotective activity of Usp10/NF-κB/Nrf2 pathway-
          [ 6 ]  蒋思怡,宋小英,张丹丹,等 . 菝葜 UPLC 指纹图谱与其                   related Morchella esculenta polysaccharide[J]. Carbohydr
              抗大鼠盆腔炎作用的谱效关系研究[J]. 中国中药杂志,                         Polym,2023,303:120453.
              2019,44(15):3323-3329.                         [20]  CHEN Y Y,CHEN S Y,CHANG H Y,et al. Phyllanthus
          [ 7 ]  沈慧敏,杨越波,方莉,等. 金刚藤胶囊治疗慢性盆腔炎                       emblica  L.  polysaccharides  ameliorate  colitis  via  micro‐
              临床疗效观察[J]. 中药材,2007,30(10):1340-1343.               biota modulation and dual inhibition of the RAGE/NF-κB
          [ 8 ]  中华中医药学会脾胃病分会. 非酒精性脂肪性肝病中医                        and MAPKs signaling pathways in rats[J]. Int J Biol Ma-
              诊疗专家共识意见:2017[J]. 临床肝胆病杂志,2017,33                   cromol,2024,258(Pt 2):129043.
              (12):2270-2274.                                [21]  SAMUEL V T,SHULMAN G I. Nonalcoholic fatty liver
          [ 9 ]  ARON-WISNEWSKY J,VIGLIOTTI C,WITJES J,et al.     disease  as  a  nexus  of  metabolic  and  hepatic  diseases[J].
              Gut microbiota and human NAFLD:disentangling micro‐  Cell Metab,2018,27(1):22-41.
              bial signatures from metabolic disorders[J]. Nat Rev Gas‐  [22]  JANI S,DA EIRA D,STEFANOVIC M,et al. The keto‐
              troenterol Hepatol,2020,17(5):279-297.              genic diet prevents steatosis and insulin resistance by re‐
          [10]  DEL  CHIERICO  F,NOBILI  V,VERNOCCHI  P,et  al.   ducing  lipogenesis,diacylglycerol  accumulation  and  pro‐
              Gut  microbiota  profiling  of  pediatric  nonalcoholic  fatty   tein kinase C activity in male rat liver[J]. J Physiol,2022,
              liver disease and obese patients unveiled by an integrated   600(18):4137-4151.
              meta-omics-based approach[J]. Hepatology,2017,65(2):  [23]  ZHANG T,MA C,ZHANG Z Q,et al. NF-κB signaling
              451-464.                                            in inflammation and cancer[J]. MedComm,2021,2(4):
          [11]  COLLINS S L,STINE J G,BISANZ J E,et al. Bile acids   618-653.
              and the gut microbiota:metabolic interactions and impacts   [24]  NAPETSCHNIG J,WU H. Molecular basis of NF-κB signa-
              on disease [J]. Nat Rev Microbiol,2023,21(4):236-247.  ling[J]. Annu Rev Biophys,2013,42:443-468.
          [12]  中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国                     [25]  XU M,XUE H,KONG L,et al. Smilax china L. polyphe‐
              医师协会脂肪性肝病专家委员会.非酒精性脂肪性肝病                            nols  improves  insulin  resistance  and  obesity  in  high-fat
              防治指南:2018 更新版[J]. 临床肝胆病杂志,2018,34                   diet-induced  mice  through  IRS/AKT-AMPK  and  NF- κB
              (5):947-957.                                        signaling  pathways[J].  Plant  Foods  Hum  Nutr,2023,78
          [13]  LIM J S,MIETUS-SNYDER M,VALENTE A,et al. The     (2):299-306.
              role  of  fructose  in  the  pathogenesis  of  NAFLD  and  the   [26]  朱韦 . 利拉鲁肽抑制 NLRP3 炎症小体活化减轻小鼠非
              metabolic  syndrome[J].  Nat  Rev  Gastroenterol  Hepatol,  酒精性脂肪性肝病的实验研究[D]. 重庆:重庆医科大
              2010,7(5):251-264.                                  学,2019.
          [14]  SUN  P  H,WANG  M  L,LIU  Y  X,et  al.  High-fat  diet-  [27]  BOARU S G,BORKHAM-KAMPHORST E,TIHAA L,
              disturbed  gut  microbiota-colonocyte  interactions  contri-   et al. Expression analysis of inflammasomes in experimen‐
              bute  to  dysregulating  peripheral  tryptophan-kynurenine   tal models of inflammatory and fibrotic liver disease[J]. J
              metabolism[J]. Microbiome,2023,11(1):154.           Inflamm(Lond),2012,9(1):49.
          [15]  LEUNG C,RIVERA L,FURNESS J B,et al. The role of             (收稿日期:2025-02-27  修回日期:2025-04-09)
              the  gut  microbiota  in  NAFLD[J].  Nat  Rev  Gastroenterol                        (编辑:舒安琴)
              Hepatol,2016,13(7):412-425.



          中国药房  2025年第36卷第11期                                              China Pharmacy  2025 Vol. 36  No. 11    · 1347 ·
   60   61   62   63   64   65   66   67   68   69   70